{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:36:10Z","timestamp":1792888570116,"version":"4.5.0"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272272"],"award-info":[{"award-number":["82272272"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bcp.2026.118083","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T19:29:20Z","timestamp":1779305360000},"page":"118083","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["A first-in-class orally available DC-SIGN agonist octaparin alleviates TNBS-induced colitis by preserving gut barrier integrity"],"prefix":"10.1016","volume":"250","author":[{"given":"Simeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaozhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingxin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfa","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118083_b0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2025.128343","article-title":"Novel plant-derived compounds modulate gut microbiome dysbiosis in colitis mice: a potential therapeutic avenue for inflammatory bowel disease","volume":"302","author":"Rahaman","year":"2026","journal-title":"Microbiol. Res."},{"key":"10.1016\/j.bcp.2026.118083_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2025.107608","article-title":"A systematic review on the role of gut microbiome in inflammatory bowel disease: Spotlight on virome and plant metabolites","volume":"205","author":"Rahaman","year":"2025","journal-title":"Microb. Pathog."},{"issue":"10080","key":"10.1016\/j.bcp.2026.118083_b0015","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/S0140-6736(16)31711-1","article-title":"Crohn's disease","volume":"389","author":"Torres","year":"2017","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.bcp.2026.118083_b0020","first-page":"132","article-title":"Global prevalence and incidence of inflammatory bowel disease: a systematic review and meta-analysis of population-based studies","volume":"18","author":"Heydari","year":"2025","journal-title":"Gastroenterol Hepatol Bed Bench"},{"issue":"10114","key":"10.1016\/j.bcp.2026.118083_b0025","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1016\/S0140-6736(17)32448-0","article-title":"Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies","volume":"390","author":"Ng","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118083_b0030","doi-asserted-by":"crossref","unstructured":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5(1):17-30.DOI:10.1016\/s2468-1253(19)30333-4.","DOI":"10.1016\/S2468-1253(19)30333-4"},{"issue":"10432","key":"10.1016\/j.bcp.2026.118083_b0035","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/S0140-6736(23)02586-2","article-title":"Crohn's disease","volume":"403","author":"Dolinger","year":"2024","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.bcp.2026.118083_b0040","doi-asserted-by":"crossref","DOI":"10.3748\/wjg.v31.i18.105472","article-title":"Current and forecasted 10-year prevalence and incidence of inflammatory bowel disease in Hong Kong, Japan, and the United States","volume":"31","author":"Zhang","year":"2025","journal-title":"World J. Gastroenterol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118083_b0045","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/00054725-199709000-00008","article-title":"Enteric Microflora in IBD: Pathogens or Commensals?","volume":"3","author":"Balfour","year":"1997","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.118083_b0050","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/00054725-200005000-00007","article-title":"Probiotics and inflammatory bowel disease: is there a scientific rationale?","volume":"6","author":"Shanahan","year":"2000","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118083_b0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/gast.2000.9159","article-title":"Commensal bacteria as targets in Crohn's disease","volume":"119","author":"Elson","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2026.118083_b0060","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms7080271","article-title":"The Role of Gut Microbiota in Intestinal Inflammation with respect to Diet and Extrinsic Stressors","author":"Lobionda","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.bcp.2026.118083_b0065","article-title":"Disturbances of the Gut Microbiota and Microbiota-Derived Metabolites in Inflammatory Bowel Disease","volume":"14(23).DOI:10.3390\/nu14235140","author":"Hu","year":"2022","journal-title":"Nutrients"},{"issue":"10","key":"10.1016\/j.bcp.2026.118083_b0070","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO guidelines on Therapeutics in Crohn's Disease: Medical Treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.bcp.2026.118083_b0075","doi-asserted-by":"crossref","unstructured":"Ruffolo C, Scarpa M, Bassi N. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010;363(11):1086-7; author reply 7-8.DOI:10.1056\/NEJMc1005805.","DOI":"10.1056\/NEJMc1005805"},{"key":"10.1016\/j.bcp.2026.118083_b0080","doi-asserted-by":"crossref","unstructured":"Pan\u00e9s J, L\u00f3pez-Sanrom\u00e1n A, Bermejo F, Garc\u00eda-S\u00e1nchez V, Esteve M, Torres Y, Dom\u00e8nech E, Piqueras M, Gomez-Garc\u00eda M, Guti\u00e9rrez A, Taxonera C, Sans M. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease. Gastroenterology 2013;145(4):766-74.e1.DOI:10.1053\/j.gastro.2013.06.009.","DOI":"10.1053\/j.gastro.2013.06.009"},{"key":"10.1016\/j.bcp.2026.118083_b0085","doi-asserted-by":"crossref","unstructured":"Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G, Jouet P, Moreau J, Mary JY, Colombel JF. Early administration of azathioprine vs conventional management of Crohn's Disease: a randomized controlled trial. Gastroenterology 2013;145(4):758-65.e2; quiz e14-5.DOI:10.1053\/j.gastro.2013.04.048.","DOI":"10.1053\/j.gastro.2013.04.048"},{"issue":"5","key":"10.1016\/j.bcp.2026.118083_b0090","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2468-1253(19)30012-3","article-title":"Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study","volume":"4","author":"Kennedy","year":"2019","journal-title":"Lancet Gastroenterol. Hepatol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118083_b0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.cgh.2019.02.044","article-title":"Comparative risk of Serious Infections with Biologic and\/or Immunosuppressive Therapy in patients with Inflammatory Bowel Diseases: a Systematic Review and Meta-Analysis","volume":"18","author":"Singh","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.bcp.2026.118083_b0100","article-title":"Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease patients Receiving Anti-TNF Therapy: Systematic Review with Meta-Analysis","volume":"13","author":"Xie","year":"2022","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.bcp.2026.118083_b0105","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of Thiopurines or Tumor Necrosis factor Antagonists Alone or in Combination and risk of Lymphoma in patients with Inflammatory Bowel Disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.bcp.2026.118083_b0110","doi-asserted-by":"crossref","DOI":"10.1080\/19490976.2025.2568055","article-title":"REG\/Reg family proteins: mediating gut microbiota homeostasis and implications in digestive diseases","volume":"17","author":"Qi","year":"2025","journal-title":"Gut Microbes"},{"issue":"5","key":"10.1016\/j.bcp.2026.118083_b0115","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1007\/s12551-023-01102-4","article-title":"Receptor basis of biological activity of polysaccharides","volume":"15","author":"Generalov","year":"2023","journal-title":"Biophys. Rev."},{"key":"10.1016\/j.bcp.2026.118083_b0120","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.3389\/fimmu.2018.01231","article-title":"Toll-like Receptor 4 triggering Promotes Cytosolic Routing of DC-SIGN-Targeted Antigens for Presentation on MHC Class I","volume":"9","author":"Horrevorts","year":"2018","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118083_b0125","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1021\/acscentsci.0c01537","article-title":"CD209L\/L-SIGN and CD209\/DC-SIGN Act as Receptors for SARS-CoV-2","volume":"7","author":"Amraei","year":"2021","journal-title":"ACS Cent. Sci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118083_b0130","first-page":"279","article-title":"DC-SIGN and immunoregulation","volume":"3","author":"Zhou","year":"2006","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.bcp.2026.118083_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2024.122782","article-title":"Preparation and structural characterization of a sulfated octasaccharide with heparin-like anticoagulant activity","volume":"347","author":"Yu","year":"2025","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.bcp.2026.118083_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107961","article-title":"Selective thrombolysis through fibrin network destabilization: an unrecognized heparin analog mechanism","volume":"221","author":"Yu","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2026.118083_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2025.103877","article-title":"Synthetic anticoagulant octaparin targets mitochondrial cardiolipin-GSDMD axis to rescue redox homeostasis in sepsis","volume":"87","author":"Zhang","year":"2025","journal-title":"Redox Biol."},{"key":"10.1016\/j.bcp.2026.118083_b0150","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.ijbiomac.2022.03.154","article-title":"Effect of in vitro simulated gastrointestinal digestion on the antioxidant activity, molecular weight, and microstructure of polysaccharides from chinese yam","volume":"207","author":"Feng","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.bcp.2026.118083_b0155","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.foodchem.2017.10.074","article-title":"Digestion under saliva, simulated gastric and small intestinal conditions and fermentation in vitro by human intestinal microbiota of polysaccharides from Fuzhuan brick tea","volume":"244","author":"Chen","year":"2018","journal-title":"Food Chem."},{"issue":"3","key":"10.1016\/j.bcp.2026.118083_b0160","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1021\/ac60147a030","article-title":"Use of Dinitrosalicylic Acid Reagent for Determination of reducing Sugar","volume":"31","author":"Miller","year":"1959","journal-title":"Anal. Chem."},{"issue":"2","key":"10.1016\/j.bcp.2026.118083_b0165","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/jpet.106.117226","article-title":"Epithelial heparin delivery via microspheres mitigates experimental colitis in mice","volume":"321","author":"Pellequer","year":"2007","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"3","key":"10.1016\/j.bcp.2026.118083_b0170","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/ibd.20753","article-title":"Distinct cytokine patterns identified from multiplex profiles of murine DSS and TNBS-induced colitis","volume":"15","author":"Alex","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"issue":"1","key":"10.1016\/j.bcp.2026.118083_b0175","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1039\/D2FO02659G","article-title":"Bifidobacterium bifidum FJSWX19M5 alleviated 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced chronic colitis by mitigating gut barrier injury and increasing regulatory T cells","volume":"14","author":"Qu","year":"2023","journal-title":"Food Funct."},{"key":"10.1016\/j.bcp.2026.118083_b0180","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.106426","article-title":"Andrographolide sulfonate ameliorates chronic colitis induced by TNBS in mice via decreasing inflammation and fibrosis","volume":"83","author":"Gao","year":"2020","journal-title":"Int. Immunopharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118083_b0185","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.4049\/jimmunol.162.4.2275","article-title":"Expression of the neutrophil chemokine KC in the colon of mice with enterocolitis and by intestinal epithelial cell lines: effects of flora and proinflammatory cytokines","volume":"162","author":"Song","year":"1999","journal-title":"J. Immunol."},{"issue":"Pt 1","key":"10.1016\/j.bcp.2026.118083_b0190","article-title":"A hemoadhican-based sponge with anti-heparin interference for treating uncontrollable massive hemorrhage","volume":"279","author":"Fang","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118083_b0195","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.jtha.2025.12.022","article-title":"A synthetic anticoagulant, octaparin, attenuates renal ischemia-reperfusion injury via dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin\/nuclear factor \u03baB signaling","volume":"24","author":"Yu","year":"2026","journal-title":"J. Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.bcp.2026.118083_b0200","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nrgastro.2013.35","article-title":"The gastrointestinal mucus system in health and disease","volume":"10","author":"Johansson","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118083_b0205","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/j.cellsig.2010.03.018","article-title":"C-type lectin DC-SIGN: an adhesion, signalling and antigen-uptake molecule that guides dendritic cells in immunity","volume":"22","author":"Svajger","year":"2010","journal-title":"Cell. Signal."},{"issue":"7","key":"10.1016\/j.bcp.2026.118083_b0210","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2217\/fmb.09.51","article-title":"Pathogen recognition by DC-SIGN shapes adaptive immunity","volume":"4","author":"Geijtenbeek","year":"2009","journal-title":"Future Microbiol."},{"issue":"7","key":"10.1016\/j.bcp.2026.118083_b0215","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s00262-008-0615-1","article-title":"Innate signaling by the C-type lectin DC-SIGN dictates immune responses","volume":"58","author":"den Dunnen","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"issue":"11","key":"10.1016\/j.bcp.2026.118083_b0220","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.7150\/ijbs.97263","article-title":"The PI3K\/Akt-Nrf2 Signaling Pathway and Mitophagy Synergistically Mediate Hydroxytyrosol to Alleviate Intestinal Oxidative damage","volume":"20","author":"Wen","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.bcp.2026.118083_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.jep.2022.116028","article-title":"PI3K\/AKT\/mTOR, NF-\u03baB and ERS pathway participated in the attenuation of H2O2-induced IPEC-J2 cell injury by koumine","volume":"304","author":"Yuan","year":"2023","journal-title":"J. Ethnopharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118083_b0230","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.trsl.2015.09.002","article-title":"Pathway-based approaches to the treatment of inflammatory bowel disease","volume":"167","author":"Bamias","year":"2016","journal-title":"Transl. Res."},{"issue":"3","key":"10.1016\/j.bcp.2026.118083_b0235","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1159\/000500721","article-title":"Mechanism-based Treatment strategies for IBD: Cytokines, Cell Adhesion Molecules, JAK Inhibitors, Gut Flora, and more","volume":"4","author":"Schreiner","year":"2019","journal-title":"Inflamm Intest Dis"},{"issue":"9","key":"10.1016\/j.bcp.2026.118083_b0240","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1016\/j.apsb.2020.11.003","article-title":"Receptor-mediated targeted drug delivery systems for treatment of inflammatory bowel disease: Opportunities and emerging strategies","volume":"11","author":"Liu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"5","key":"10.1016\/j.bcp.2026.118083_b0245","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41423-020-0412-0","article-title":"Neutrophil chemoattractant receptors in health and disease: double-edged swords","volume":"17","author":"Metzemaekers","year":"2020","journal-title":"Cell. Mol. Immunol."},{"issue":"2","key":"10.1016\/j.bcp.2026.118083_b0250","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jcmgh.2022.05.003","article-title":"Robust Colonic Epithelial Regeneration and Amelioration of Colitis via FZD-Specific Activation of Wnt Signaling","volume":"14","author":"Xie","year":"2022","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118083_b0255","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/ecco-jcc\/jjaa182","article-title":"The JAK Inhibitor Tofacitinib Rescues Intestinal Barrier Defects Caused by Disrupted Epithelial-macrophage Interactions","volume":"15","author":"Spalinger","year":"2021","journal-title":"J. Crohns Colitis"},{"issue":"4","key":"10.1016\/j.bcp.2026.118083_b0260","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00078-24","article-title":"Akkermansia muciniphila and Parabacteroides distasonis synergistically protect from colitis by promoting ILC3 in the gut","volume":"15","author":"Gaifem","year":"2024","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.bcp.2026.118083_b0265","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13099-024-00635-7","article-title":"The influence of Akkermansia muciniphila on intestinal barrier function","volume":"16","author":"Mo","year":"2024","journal-title":"Gut Pathog"},{"key":"10.1016\/j.bcp.2026.118083_b0270","article-title":"Parabacteroides distasonis Properties Linked to the selection of New Biotherapeutics","volume":"14(19).DOI:10.3390\/nu14194176","author":"Chamarande","year":"2022","journal-title":"Nutrients"},{"issue":"12","key":"10.1016\/j.bcp.2026.118083_b0275","doi-asserted-by":"crossref","first-page":"690","DOI":"10.5414\/CPP42690","article-title":"A comparison of observational studies and controlled trials of heparin in ulcerative colitis","volume":"42","author":"Malhotra","year":"2004","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2026.118083_b0280","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ibd.20085","article-title":"Randomized, placebo-controlled trial of low molecular weight heparin in active ulcerative colitis","volume":"13","author":"de Bi\u00e8vre","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"issue":"6","key":"10.1016\/j.bcp.2026.118083_b0285","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.4049\/jimmunol.174.6.3237","article-title":"Probiotics ameliorate recurrent Th1-mediated murine colitis by inducing IL-10 and IL-10-dependent TGF-beta-bearing regulatory cells","volume":"174","author":"Di Giacinto","year":"2005","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.bcp.2026.118083_b0290","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1002\/ibd.20369","article-title":"Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells","volume":"14","author":"Pronio","year":"2008","journal-title":"Inflamm. Bowel Dis."},{"issue":"2","key":"10.1016\/j.bcp.2026.118083_b0295","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1476-5381.2011.01226.x","article-title":"Inhibitor of PI3K\u03b3 ameliorates TNBS-induced colitis in mice by affecting the functional activity of CD4+CD25+FoxP3+ regulatory T cells","volume":"163","author":"Dutra","year":"2011","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118083_b0300","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/rheumatology\/keq328","article-title":"FoxP3+ CD4+ T cells in systemic autoimmune diseases: the delicate balance between true regulatory T cells and effector Th-17 cells","volume":"50","author":"Abdulahad","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.bcp.2026.118083_b0305","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.0105-2896.2005.00250.x","article-title":"Regulatory T cells and intestinal homeostasis","volume":"204","author":"Coombes","year":"2005","journal-title":"Immunol. Rev."},{"issue":"5838","key":"10.1016\/j.bcp.2026.118083_b0310","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1126\/science.1142331","article-title":"Emerging challenges in regulatory T cell function and biology","volume":"317","author":"Sakaguchi","year":"2007","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.bcp.2026.118083_b0315","doi-asserted-by":"crossref","first-page":"5012","DOI":"10.4049\/jimmunol.171.10.5012","article-title":"CD4+CD25+ regulatory T cells cure murine colitis: the role of IL-10, TGF-beta, and CTLA4","volume":"171","author":"Liu","year":"2003","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.bcp.2026.118083_b0320","doi-asserted-by":"crossref","first-page":"5852","DOI":"10.4049\/jimmunol.177.9.5852","article-title":"Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis","volume":"177","author":"Uhlig","year":"2006","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118083_b0325","doi-asserted-by":"crossref","first-page":"15542","DOI":"10.1038\/s41598-025-98771-w","article-title":"Comprehensive computational strategies for multi-target drug discovery in inflammatory bowel disease utilizing bioactive compounds","volume":"15","author":"Mansouri","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.bcp.2026.118083_b0330","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1097\/FTD.0000000000000627","article-title":"Improving Therapeutic Decisions: Pharmacodynamic monitoring as an Integral Part of Therapeutic Drug monitoring","volume":"41","author":"Shipkova","year":"2019","journal-title":"Ther. Drug Monit."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226004181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T00:32:46Z","timestamp":1792888366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226004181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":66,"alternative-id":["S0006295226004181"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118083","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A first-in-class orally available DC-SIGN agonist octaparin alleviates TNBS-induced colitis by preserving gut barrier integrity","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118083"}}